Satisfaction and Efficacy Outcomes When Switching from Injectable Disease-Modifying Therapies to Fingolimod in PREFERMS: Effect of Previous Treatment

被引：0
|
作者：
Hunter, Samuel F. [1 ]
Cree, Bruce A. C. [2 ]
Meng, Xiangyi [3 ]
Schofield, Lesley [3 ]
Kolodny, Scott [3 ]
Tenenbaum, Nadia [3 ]
Thomas, Florian P. P. [4 ]
机构：
[1] Adv Neurosci Inst, Franklin, TN USA
[2] UCSF Weill Inst Neurosci, San Francisco, CA USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Hackensack Univ Med Ctr, Hackensack, NJ USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P019
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [1] Effect of previous therapies on treatment retention and satisfaction in patients randomized to fingolimod or injectable disease-modifying therapies in PREFERMS
    Thomas, Florian P.
    Hunter, Samuel F.
    Meng, Xiangyi
    Schofield, Lesley
    Kolodny, Scott
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    [J]. NEUROLOGY, 2018, 90
  • [2] Effect of Treatment Naivete on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS
    Hunter, Samuel F.
    Thomas, Florian P.
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    [J]. NEUROLOGY, 2019, 92 (15)
  • [3] Effect of Treatment Naivete on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS
    Hunter, Samuel F.
    Thomas, Florian P.
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 35 - 36
  • [4] Switching to fingolimod in PREFERMS: Effect of treatment history and naivety on clinical, MRI and treatment satisfaction outcomes
    Hunter, Samuel F.
    Thomas, Florian P.
    Cascione, Mark
    Williams, Ian M.
    Meng, Xiangyi
    Schofield, Lesley
    Weiss, Jamie L.
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 45
  • [5] Real-World Patient Retention and Satisfaction on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis; Results from PREFERMS
    Crayton, Heidi
    Steingo, Brian
    Huang, Deren
    Meng, Xiangyi
    Schofield, Lesley
    Johnson, Kristen
    Tenenbaum, Nadia
    [J]. NEUROLOGY, 2016, 86
  • [6] Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies
    Van Wijmeersch, B.
    Buffels, R.
    Clinch, S.
    Kuhelj, R.
    Wei, W.
    Vermersch, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 824 - 825
  • [7] Post hoc results from PREFERMS: Volumetric MRI outcomes adjusted for exposure to fingolimod versus platform injectable disease-modifying therapies in early relapsing-remitting multiple sclerosis
    Arnold, Douglas L.
    Hunter, Samuel
    Cree, Bruce
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    [J]. NEUROLOGY, 2016, 87 (02) : E24 - E24
  • [8] Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis
    Eagle, Tessa
    Stuart, Fiona
    Chua, Alicia S.
    LaRussa, Allison
    Leclaire, Kaitlynne
    Cook, Sandra L.
    Chitnis, Tanuja
    Weiner, Howard L.
    Glanz, Bonnie I.
    Healy, Brian C.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 196 - 201
  • [9] Persistence with multiple sclerosis disease-modifying therapies is highest when switching to fingolimod compared with other oral and injectable therapies: a retrospective US claims database analysis
    Korn, Jonathan
    Medin, Jennie
    Fang, Juanzhi
    Putzki, Norman
    [J]. NEUROLOGY, 2017, 88
  • [10] Key Results fro PREFERMS: Real-World Patient Retention and Outcomes on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis
    Cree, Bruce
    Wynn, Daniel
    Cascione, Mark
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    [J]. NEUROLOGY, 2016, 86
12345